Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-109761
Filing Date
2025-08-18
Accepted
2025-08-18 16:31:41
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 16157
2 EX-99.1 ck0000000000-ex99_1.pdf EX-99.1 78547
3 EX-99.A(1) ck0000000000-ex99_a1.pdf EX-99.A(1) 77676
  Complete submission text file 0000950170-25-109761.txt   233536
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Subject) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91132 | Film No.: 251228328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address HALDOR TOPSOE ALLE 1 KONGENS LYNGBY G7 2800
Business Address HALDOR TOPSOE ALLE 1 KONGENS LYNGBY G7 2800 45 4527 2000
Topsoe Holding A/S (Filed by) CIK: 0001788357 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A